CD56 does not contribute to the antitumor, tissue homing, and glycolytic capacity of human NK cells
Journal of Leukocyte Biology · 2025
DOI: 10.1093/jleuko/qiae227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2025. Verfasst von Ana L Portillo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, McMaster Children's Hospital, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada. Hauptthemen laut MEDLINE: Killer Cells, Natural, CD56 Antigen, Glycolysis, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Ontario Ministry of Health and Long-Term Care, CIHR Master's Canada Graduate Scholarship, Ontario Graduate Fellowship.
Abstract (Originalsprache)
Natural killer (NK) cells are critical innate immune cells involved in the clearance of virally infected and malignant cells. Human NK cells are distinguished by their surface expression of CD56 and a lack of CD3. While CD56 expression and cell surface density has long been used as the prototypic marker to characterize primary human NK cell functional subsets, the exact functional role of CD56 in primary human NK cells is still not fully understood. Here, we eliminated the expression of CD56 in human ex vivo expanded NK cells (CD56bright) using CRISPR/Cas9 in order to assess the function of CD56 in this highly activated and cytotoxic NK cell population. We show that the expression of CD56 has no effect on NK cell proliferative capacity or expression of various activation and inhibitory markers. Further, CD56 does not contribute to NK cell–mediated cytotoxicity, inflammatory cytokine production, or the ability of NK cells to control tumor engraftment in vivo. We also found that while deletion of CD56 did not impact NK cell glycolytic metabolism, it did increase NK cell reliance on oxidative phosphorylation. Last, CD56 does not alter expanded NK cell in vivo tissue trafficking. Our results indicate that while CD56 expression could be used to indicate a hyperfunctional state of NK cells, it does not directly influence the antitumor functions of expanded NK cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, McMaster University, McMaster Children's Hospital, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada.
- McMaster Immunology Research Centre, McMaster University, MDCL 4010, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada.
- Centre for Discovery in Cancer Research, McMaster University, MDCL 5106, 1280 Main Street West, Hamilton, ON L8S 4M1, Canada.
ORCID-Profile: Ali A Ashkar
Förderung
- Ontario Ministry of Health and Long-Term Care
- CIHR Master's Canada Graduate Scholarship
- Ontario Graduate Fellowship
- CIHR Doctoral Canada Graduate Scholarships
- CIHR Master’s Canada Graduate Scholarship
Zitieren
APA
Portillo, A. L., Rojas, E. A., Mehboob, M., Moinuddin, A., Balint, E., Feng, E., Silvestri, C., Vahedi, F., Ritchie, T. M., Mansour, A. J., Bramson, J. L., & Ashkar, A. A. (2025). CD56 does not contribute to the antitumor, tissue homing, and glycolytic capacity of human NK cells. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiae227
Vancouver
Portillo AL, Rojas EA, Mehboob M, Moinuddin A, Balint E, Feng E, et al. CD56 does not contribute to the antitumor, tissue homing, and glycolytic capacity of human NK cells. Journal of Leukocyte Biology. 2025. doi:10.1093/jleuko/qiae227
BibTeX
@article{Portillo2025,
author = {Portillo, Ana L and Rojas, Eduardo A and Mehboob, Misaal and Moinuddin, Adnan and Balint, Elizabeth and Feng, Emily and Silvestri, Christopher and Vahedi, Fatemeh and Ritchie, Tyrah M and Mansour, Alexa J and Bramson, Jonathan L and Ashkar, Ali A},
title = {CD56 does not contribute to the antitumor, tissue homing, and glycolytic capacity of human NK cells},
journal = {Journal of Leukocyte Biology},
year = {2025},
doi = {10.1093/jleuko/qiae227}
}
EUVIMED